2020
Use of Intravenous Gadolinium-Based Contrast Media in Patients With Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation
Weinreb JC, Rodby RA, Yee J, Wang CL, Fine D, McDonald RJ, Perazella MA, Dillman JR, Davenport MS. Use of Intravenous Gadolinium-Based Contrast Media in Patients With Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation. Kidney Medicine 2020, 3: 142-150. PMID: 33604544, PMCID: PMC7873723, DOI: 10.1016/j.xkme.2020.10.001.Peer-Reviewed Original ResearchNephrogenic systemic fibrosisNational Kidney FoundationKidney diseaseGroup IIConsensus statementKidney FoundationAmerican CollegeRisk of NSFContrast mediumAcute kidney injuryAdvanced kidney diseaseCare of patientsGadolinium-based contrast mediaKidney injuryDialysis initiationClinical indicationsSystemic fibrosisPatientsIntravenous gadoliniumUnconfounded casesDiseasePotential harmRadiologyRiskFibrosisUse of Intravenous Gadolinium-based Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation
Weinreb JC, Rodby RA, Yee J, Wang CL, Fine D, McDonald RJ, Perazella MA, Dillman JR, Davenport MS. Use of Intravenous Gadolinium-based Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation. Radiology 2020, 298: 202903. PMID: 33170103, DOI: 10.1148/radiol.2020202903.Peer-Reviewed Original ResearchConceptsNephrogenic systemic fibrosisNational Kidney FoundationKidney diseaseGroup IIConsensus statementKidney FoundationAmerican CollegeRisk of NSFContrast mediumAcute kidney injuryAdvanced kidney diseaseCare of patientsGadolinium-based contrast mediaSimultaneous joint publicationKidney injuryDialysis initiationClinical indicationsSystemic fibrosisPatientsIntravenous gadoliniumUnconfounded casesDiseasePotential harmRadiologyRisk
2017
Crizotinib: Renal Safety Evaluation
Perazella M, Izzedine H. Crizotinib: Renal Safety Evaluation. Journal Of Onco-Nephrology 2017, 1: 49-56. DOI: 10.5301/jo-n.5000012.Peer-Reviewed Original ResearchNon-small cell lung cancerAdvanced ALK-positive non-small cell lung cancerALK-positive non-small cell lung cancerPositive non-small cell lung cancerAnaplastic lymphoma kinase-1Renal adverse effectsAcute kidney injuryAdverse renal effectsInsulin receptor tyrosine kinase familyCell lung cancerMechanism of actionKidney injuryPeripheral edemaRenal effectsElectrolyte disordersLung cancerClinical indicationsClinical trialsRenal cystsALK inhibitorsReceptor tyrosine kinase familySmall molecule inhibitorsCrizotinibClinical useAdverse effects